Aripiprazole (Abilify)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Major Depressive Disorder, Schizophrenia, Bipolar Disorder

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (1)
EU
  • Abilify is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older. Abilify is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment. Abilify is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.
Product first approved 2004EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (92)
Bipolar Disorder
NCT02918370 · University of Texas Southwestern Medical Center
2016-11 – 2023-06-30 · Bipolar Disorder, Alcoholism, Alcohol Abuse
What this study did
NCT01710709 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2012-11 – 2016-12 · Bipolar I
What this study did
NCT01122927 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2010-07 – 2014-09 · Adolescent Schizophrenia, Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features
What this study did
NCT01520350 · Serge Beaulieu
2012-02 – 2013-06 · Bipolar Disorder, Depressive Episode
What this study did
NCT00194012 · University Hospitals Cleveland Medical Center
2004-08 – 2012-06 · Bipolar Disorder
What this study did
NCT00665366 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2008-06 – 2011-10 · Bipolar Disorder Mania
What this study did
NCT00194077 · University Hospitals Cleveland Medical Center
2004-08 – 2011-01 · Bipolar Disorder
What this study did
NCT00857818 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2009-04 – 2010-03 · Schizophrenia, Schizoaffective Disorder, Bipolar I Disorder, Metabolic Syndrome
What this study did
NCT00288353 · Northwestern University
2006-01 – 2008-12 · Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
What this study did
NCT00221416 · University of Cincinnati
2005-06 – 2008-12 · Bipolar Disorder
What this study did
NCT00257972 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2004-10 – 2007-12 · Bipolar Disorder
What this study did
NCT00338273 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2006-12 – 2007-11 · Bipolar Disorder
What this study did
NCT00095511 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2004-06 – 2007-05 · Bipolar Disorder
What this study did
NCT00110461 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2005-03 – 2007-02 · Bipolar Disorder
What this study did
NCT00102518 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2004-09 – 2007-02 · Schizophrenia, Bipolar Disorder
What this study did
NCT00097266 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2004-12 – 2007-01 · Bipolar Disorder
What this study did
NCT00094432 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2004-06 – 2006-11 · Bipolar I Disorder
What this study did
NCT00036348 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2000-03 – 2003-06 · Bipolar Disorder
What this study did
Major Depressive Disorder
NCT01655706 · University Health Network, Toronto
2012-04-23 – 2017-01 · Major Depressive Disorder
What this study did
NCT01421342 · VA Office of Research and Development
2012-12 – 2016-06 · Major Depressive Disorder
What this study did
NCT00876343 · Otsuka Pharmaceutical Co., Ltd.
2009-03 – 2012-07 · Major Depressive Disorder
What this study did
NCT00882362 · Otsuka Pharmaceutical Co., Ltd.
2009-03 – 2012-07 · Major Depressive Disorder
What this study did
NCT01111552 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2010-07-29 – 2011-09-27 · Major Depressive Disorder (MDD)
What this study did
NCT01123707 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2010-11-18 – 2011-09-27 · Major Depressive Disorder (MDD)
What this study did
NCT01111539 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2010-07-13 – 2011-09-20 · Major Depressive Disorder (MDD)
What this study did
NCT01111565 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2010-10-04 – 2011-09-01 · Major Depressive Disorder (MDD)
What this study did
NCT00276978 · University Hospital Freiburg
2005-06 – 2009-11 · Therapy-resistant Depression
What this study did
NCT00683852 · Massachusetts General Hospital
2008-09 – 2009-09 · Major Depressive Disorder
What this study did
NCT00105196 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2005-03 – 2008-03 · Major Depressive Disorder
What this study did
NCT00556140 · Massachusetts General Hospital
2003-06 – 2008-01 · Psychotic Depression
What this study did
NCT00095745 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2004-09 – 2007-11 · Major Depressive Disorder
What this study did
NCT00080314 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2004-01 – 2006-10 · Bipolar Disorder
What this study did
Schizophrenia
NCT03510325 · Shanghai Mental Health Center
2019-02-12 – 2023-09-27 · Schizophrenia
What this study did
NCT03172871 · Otsuka Beijing Research Institute
2017-05-15 – 2019-09-30 · Schizophrenia
What this study did
NCT02374567 · Hannover Medical School
2015-01 – 2017-06-28 · Dementia, Depression, Schizophrenia, Psychosomatic Disorders, Anxiety Disorders
What this study did
NCT01942148 · Otsuka Pharmaceutical Co., Ltd.
2010-08 – 2015-11 · Schizophrenia
What this study did
NCT01959035 · H. Lundbeck A/S
2013-10 – 2015-03 · Schizophrenia
What this study did
NCT01795547 · H. Lundbeck A/S
2013-02 – 2014-09 · Schizophrenia
What this study did
NCT02054702 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2014-02 – 2014-07 · Schizophrenia
What this study did
NCT01149655 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2011-07 – 2013-12 · Schizophrenia
What this study did
NCT01432444 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2011-09 – 2013-12 · Schizophrenia
What this study did
NCT00731549 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2008-12 – 2013-11 · Schizophrenia
What this study did
Phase 2/3 (5)
Schizophrenia
NCT03485417 · The University of Hong Kong
2019-06-01 – 2025-05-31 · Stimulant Use With Stimulant-Induced Psychotic Disorder (Diagnosis), Schizophrenia and Related Disorders, Stimulant Dependence, Stimulant Abuse, Pharmacotherapy
What this study did
NCT01942161 · Otsuka Pharmaceutical Co., Ltd.
2010-08 – 2014-11 · Schizophrenia
What this study did
NCT00237874 · Yale University
2004-02 – 2007-02 · Schizophrenia, Psychosis
What this study did
Other / comorbidity
NCT00884884 · National Institute on Alcohol Abuse and Alcoholism (NIAAA)
2007-09 – 2015-10 · Alcohol Dependence
What this study did
NCT00910780 · Washington University School of Medicine
2009-11 – 2009-11 · Diabetes
What this study did
Phase 2 (21)
Major Depressive Disorder
NCT07810738 · Washington University School of Medicine
2026-11-01 – 2029-09-15 · Late Life Treatment Resistant Depression, Depression - Major Depressive Disorder, Treatment Resistant Depression
What this study did
NCT02722967 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2016-03 – 2016-09 · Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
What this study did
Schizophrenia
NCT02462473 · Janssen Research & Development, LLC
2015-05 – 2016-01 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00737256 · Paul Saenger
2008-08 – 2014-05 · Schizophrenia, Cocaine Dependence
What this study did
NCT00202007 · Otsuka Beijing Research Institute
2005-02 – 2005-07 · Schizophrenia
What this study did
Other / comorbidity
NCT04539951 · Shanghai Mental Health Center
2020-09-22 – 2028-12-31 · Obsessive-Compulsive Disorder
What this study did
NCT07714213 · Christiana Franke
2026-10-01 – 2028-12-31 · Post-acute Infectious Syndrome (PAIS), Post-COVID-19 Condition (PCC or Long COVID)
What this study did
NCT05545891 · University of Chicago
2026-06 – 2027-12 · Trichotillomania (Hair-Pulling Disorder), Dermatillomania
What this study did
NCT02574741 · University of California, Los Angeles
2012-06 – 2019-12 · Autism Spectrum Disorder
What this study did
NCT00489866 · Durham VA Medical Center
2007-03 – 2014-12 · PTSD
What this study did
NCT00619190 · University of North Carolina, Chapel Hill
2006-01 – 2012-06 · Autistic Disorder, Asperger Syndrome, Autism Spectrum Disorder
What this study did
NCT00497055 · San Francisco Department of Public Health
2009-03 – 2012-03 · Substance Abuse, HIV Infections
What this study did
NCT00208533 · Drexel University College of Medicine
2004-02 – 2011-11-16 · Autism
What this study did
NCT00667875 · Medical University of South Carolina
2008-04 – 2011-05 · Alcohol Dependence
What this study did
NCT00420459 · Indiana University
2007-04 – 2010-03 · Fragile X Syndrome
What this study did
NCT00279409 · New York State Psychiatric Institute
2006-07 – 2009-02 · Attention Deficit Hyperactivity Disorder
What this study did
NCT00308074 · Cambridge Health Alliance
2006-02 – 2009-02 · Autism, Asperger's Disorder, Pervasive Developmental Disorder
What this study did
NCT00373880 · New York State Psychiatric Institute
2005-04 – 2008-09 · Cocaine Abuse
What this study did
NCT00198055 · Indiana University
2005-01 – 2007-09 · Asperger's Disorder, Pervasive Developmental Disorder
What this study did
NCT00183235 · Medical University of South Carolina
2005-06 – 2006-02 · Alcohol Dependence
What this study did
NCT00174876 · State University of New York - Upstate Medical University
2004-07 – 2005-05 · Depression
What this study did
Phase 1/2 (2)
Schizophrenia
NCT02650102 · Shanxi Medical University
2013-01 – 2016-12 · Schizophrenia
What this study did
Other / comorbidity
NCT05814640 · First Affiliated Hospital of Chongqing Medical University
2023-02-20 – 2027-07-01 · Depression, Sequestra
What this study did
Phase 1 (25)
Bipolar Disorder
NCT03854409 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2019-01-31 – 2020-02-20 · Schizophrenia, Bipolar I Disorder
What this study did
NCT02087579 · Janssen Research & Development, LLC
2014-02 – 2014-12 · Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
What this study did
NCT00321516 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2006-07 – 2007-02 · Bipolar Disorder
What this study did
Major Depressive Disorder
NCT03790085 · Tianjin Medical University General Hospital
2018-09-01 – 2020-12-31 · Schizophrenia, Major Depressive Disorder, Anxiety Disorders
What this study did
Schizophrenia
NCT03150771 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2017-06-14 – 2018-05-02 · Schizophrenia
What this study did
NCT02501109 · CMG Pharmaceutical Co. Ltd
2015-10 – 2016-03 · Schizophrenia
What this study did
NCT01646827 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2012-05 – 2013-04 · Schizophrenia
What this study did
NCT01552772 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2012-01 – 2012-04 · Schizophrenia
What this study did
NCT00466310 · Duke University
2007-02 – 2011-01 · Schizophrenia
What this study did
NCT01870999 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2007-11 – 2008-10 · Schizophrenia
What this study did
NCT00102479 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2004-07-01 – 2005-07-01 · Schizophrenia, Mania
What this study did
Other / comorbidity
NCT07215884 · University of California, San Francisco
2025-09-30 – 2027-08-30 · Stuttering, Adult
What this study did
NCT02634463 · Janssen Research & Development, LLC
2015-11-09 – 2016-11-09 · Immunoassay, Antipsychotic
What this study did
NCT02088697 · Otsuka Pharmaceutical Co., Ltd.
2013-12 – 2014-01 · Healthy Volunteers
What this study did
NCT00780702 · National Institute on Drug Abuse (NIDA)
2008-05-08 – 2013-04-16 · Cocaine Dependence, Cocaine-Related Disorders, Opioid-Related Disorders
What this study did
NCT01607762 · Janssen Research & Development, LLC
2012-02 – 2012-10 · Healthy
What this study did
NCT00276874 · Craig Rush
2006-01 – 2012-01 · Cocaine-Related Disorders
What this study did
NCT01424449 · GlaxoSmithKline
2010-01 – 2010-07 · Depressive Disorder
What this study did
NCT00689559 · AstraZeneca
2008-03 – 2009-04 · Alzheimer's Disease
What this study did
NCT00361790 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2006-08 – 2006-11 · Healthy
What this study did
NCT00362271 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2006-08 – 2006-09 · Healthy
What this study did
NCT00089440 · National Institute on Drug Abuse (NIDA)
2004-06 – 2005-03 · Amphetamine-Related Disorders
What this study did
Phase 4 (122)
Bipolar Disorder
NCT06433635 · Massachusetts General Hospital
2024-10-01 – 2030-02-28 · Bipolar I Disorder, Depression
What this study did
NCT01710163 · University of Sao Paulo
2012-06 – 2015-06 · Bipolar I Disorder
What this study did
NCT00484471 · Korea Otsuka International Asia Arab
2007-10 – 2012-11 · Bipolar Disorder
What this study did
NCT00845988 · Seoul National University Hospital
2008-12 – 2012-03 · Bipolar Disorders, Metabolic Complication
What this study did
NCT00205699 · Washington University School of Medicine
2006-04 – 2011-07 · Aggression, Attention Deficit-Hyperactivity, Oppositional Defiant Disorder, Pervasive Development Disorders, Bipolar Disorder
What this study did
NCT00545675 · Korea Otsuka Pharmaceutical Co., Ltd.
2007-12 – 2010-07 · Bipolar Disorder
What this study did
NCT00545142 · Korea Otsuka Pharmaceutical Co., Ltd.
2007-10 – 2010-06 · Bipolar Disorder
What this study did
NCT00592683 · Massachusetts General Hospital
2007-12 – 2010-04 · Pediatric Bipolar Disorder
What this study did
NCT00261443 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2005-09 – 2009-10 · Bipolar Disorder
What this study did
NCT00223496 · The University of Texas Health Science Center at San Antonio
2004-09 – 2009-09 · Bipolar Disorder
What this study did
NCT00277212 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2005-12-01 – 2009-07-01 · Bipolar Disorder
What this study did
NCT00305370 · Federal University of Rio Grande do Sul
2005-08 – 2008-03 · Bipolar Disorder, Attention Deficit Hyperactivity Disorder
What this study did
NCT00224822 · New Mexico VA Healthcare System
2004-03 – 2007-03 · Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Metabolic Syndrome X
What this study did
NCT00181779 · Massachusetts General Hospital
2003-02 – 2006-12 · Bipolar Disorder, Mania
What this study did
NCT00194038 · University Hospitals Cleveland Medical Center
2004-04 – 2006-06 · Bipolar Disorder
What this study did
Major Depressive Disorder
NCT07011693 · Xinyu Zhou
2025-06-20 – 2027-12 · Major Depressive Disorder (MDD)
What this study did
NCT05531591 · Centre for Addiction and Mental Health
2019-08-01 – 2024-07-31 · Depression, Dementia, Mild Cognitive Impairment, Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression, Late Life Depression, Geriatric Depression
What this study did
NCT02977299 · Massachusetts General Hospital
2017-07-13 – 2022-04-24 · Treatment Resistant Major Depressive Disorder
What this study did
NCT02960763 · Washington University School of Medicine
2017-02-24 – 2021-09-01 · Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression, Late Life Depression, Geriatric Depression
What this study did
NCT01696617 · Seoul National University Hospital
2012-02-10 – 2019-02 · Major Depressive Disorder
What this study did
NCT03643159 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2018-06-28 – 2018-10-17 · Schizophrenia, Bipolar 1 Disorder, Major Depressive Disorder
What this study did
NCT01942187 · New York State Psychiatric Institute
2013-08 – 2015-12 · Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder Not Otherwise Specified (NOS)
What this study did
NCT01429831 · Taiwan Otsuka Pharm. Co., Ltd
2011-09 – 2013-05 · Major Depressive Disorder
What this study did
NCT00608543 · University of Texas Southwestern Medical Center
2005-10 – 2009-01 · Major Depressive Disorder
What this study did
NCT00220636 · St. Luke's-Roosevelt Hospital Center
2005-03 – 2008-01 · Depressive Disorder, Major
What this study did
NCT00208169 · Creighton University
2005-03 – 2007-06 · Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Anxiety Disorders, Substance Abuse
What this study did
Schizophrenia
NCT06969755 · Northwell Health
2024-09-04 – 2030-07-30 · Schizophenia Disorder
What this study did
NCT06060886 · Consorcio Centro de Investigación Biomédica en Red (CIBER)
2023-11-01 – 2025-12-31 · Schizophrenia, Treatment-resistant Schizophrenia, Side Effect, Lipid Metabolism Disorders, Diabetes, NAFLD, Psychosis
What this study did
NCT06236451 · All India Institute of Medical Sciences, Bhubaneswar
2024-04-05 – 2025-11-12 · Schizophrenia
What this study did
NCT05322031 · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
2022-08-01 – 2024-11-30 · Schizophrenia, Myelin Degeneration, Cognition Disorder
What this study did
NCT05766540 · All India Institute of Medical Sciences, Bhubaneswar
2023-08-20 – 2023-12-31 · Difference in the Change in Cardiovascular Risk in Treatment Resistant Schizophrenia
What this study did
NCT04446234 · Shanghai Mental Health Center
2021-05 – 2022-12-31 · Schizophrenia
What this study did
NCT03090503 · Fundación Marques de Valdecilla
2014-06 – 2021-06 · Schizophrenia, Psychotic Disorders, Psychosis
What this study did
NCT03289026 · Peking University
2017-09-01 – 2021-02-02 · Acute Schizophrenia Episode
What this study did
NCT02339844 · University of Copenhagen
2014-01 – 2021-01 · Schizophrenia
What this study did
NCT03883204 · Fundación Marques de Valdecilla
2015-01-01 – 2020-12 · Schizophrenia, Psychotic Disorders, Psychosis
What this study did
NCT02532491 · Fundación Marques de Valdecilla
2014-05 – 2020-12 · Schizophrenia, Psychotic Disorders
What this study did
NCT03839251 · Chonbuk National University Hospital
2018-06-01 – 2020-09-30 · Schizophrenia
What this study did
NCT02146547 · UMC Utrecht
2015-02 – 2020-08-26 · Schizophrenia
What this study did
NCT03568500 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2018-05-21 – 2019-09-06 · Schizophrenia, Schizoaffective Disorder, First Episode Psychosis
What this study did
NCT02697045 · Abdi İbrahim Otsuka
2017-01-04 – 2018-03-31 · Schizophrenia
What this study did
NCT02282085 · Matt Byerly
2014-12 – 2017-12 · Schizophrenia
What this study did
NCT01446328 · Haukeland University Hospital
2011-10 – 2017-12 · Schizophrenia, Psychotic Disorders
What this study did
NCT01913327 · University of California, San Francisco
2013-04 – 2017-01 · Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
What this study did
NCT00320671 · Northwell Health
2005-12 – 2015-12 · Schizophrenia
What this study did
NCT02526030 · Fundación Marques de Valdecilla
2008-10 – 2015-06 · Schizophrenia, Psychotic Disorders
What this study did
NCT02305823 · Fundación Marques de Valdecilla
2005-10 – 2014-05 · Schizophrenia, Psychotic Disorders
What this study did
NCT01164059 · University of Bremen
2010-02 – 2014-03 · Schizophrenia
What this study did
Early phase / not applicable (36)
Bipolar Disorder
NCT00531518 · MaineHealth
2007-10 – 2013-09 · Schizophrenia, Bipolar Disorder, Depression, Psychotic Disorders
What this study did
NCT00746252 · University of Maryland, Baltimore
2008-06 – 2010-10 · Bipolar Disorder
What this study did
NCT00665444 · University of Pittsburgh
2008-04 – 2009-08 · Bipolar Disorder, Metabolic Syndrome
What this study did
NCT00288366 · Northwestern University
2006-01 – 2008-12 · Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
What this study did
NCT00116259 · Federal University of Rio Grande do Sul
2005-03 – 2008-02 · Bipolar Disorder, Attention Deficit Hyperactivity Disorder
What this study did
NCT00226317 · Cambridge Health Alliance
2004-04 – 2008-02 · Bipolar Disorder
What this study did
Major Depressive Disorder
NCT06937476 · Central South University
2025-05-08 – 2026-04-29 · Major Depressive Disorder (MDD), Rumination
What this study did
NCT05389046 · Peking University
2022-08-15 – 2025-12 · Outpatients / Inpatients With Depression
What this study did
NCT06372210 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2023-06-26 – 2023-07-19 · Mental Disorder, Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
What this study did
NCT01488266 · Korea University
2011-11 – 2013-03 · Major Depressive Disorder
What this study did
NCT00953745 · Washington University School of Medicine
2009-05 – 2012-12 · Major Depressive Disorder
What this study did
NCT00873795 · Chimei Medical Center
2007-04 – 2009-03 · Major Depressive Disorder
What this study did
Schizophrenia
NCT02926976 · Shanghai Mental Health Center
2016-11 – 2019-09 · Schizophrenia
What this study did
NCT02007928 · Centre Hospitalier Universitaire de Nice
2013-04 – 2017-07 · Dissociative Disorders, Schizophrenia
What this study did
NCT02717130 · Florida Atlantic University
2016-06-08 – 2017-05-25 · Schizophrenia
What this study did
NCT01338298 · University of Maryland, Baltimore
2011-01 – 2016-12 · Hyperprolactinemia
What this study did
NCT01154829 · University of Copenhagen
2008-12 – 2016-05 · Schizophrenia
What this study did
NCT02013232 · Beijing HuiLongGuan Hospital
2013-02 – 2014-02 · Schizophrenia
What this study did
NCT00209027 · Emory University
2005-04 – 2011-04 · Schizophrenia
What this study did
NCT01057849 · Peking University
2008-09 – 2011-03 · Schizophrenia
What this study did
NCT00567099 · New Mexico VA Healthcare System
2003-08 – 2008-09 · Schizophrenia, Sensory Gating
What this study did
NCT00374348 · Jamaica Hospital Medical Center
2005-03 – 2008-05 · Schizophrenia OCD, Obsessive Compulsive Disorder
What this study did
NCT00169949 · Northwell Health
2004-01 – 2006-05 · Prodromal Schizophrenia, Prodromal Psychosis
What this study did
NCT00211380 · Louisiana State University Health Sciences Center Shreveport
2003-08 – 2006-02 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00211302 · Louisiana State University Health Sciences Center Shreveport
2003-08 – 2006-02 · Schizophrenia, Schizoaffective Disorder
What this study did
Other / comorbidity
NCT05868720 · All India Institute of Medical Sciences, Bhubaneswar
2023-07-01 – 2025-03-02 · The Goal of This Trial is to to Compare the Effect of Risperidone vs Aripiprazole in Terms of Change in Serum Glutathione Level
What this study did
NCT04765085 · Children's Hospital of Fudan University
2021-03 – 2022-09 · Tic Disorders
What this study did
NCT03232710 · Chengdu Kanghong Pharmaceutical Group Co., Ltd.
2017-06-26 – 2018-06-30 · Bioequivalence
What this study did
NCT03358277 · Tri-Service General Hospital (TSGH)
2014-11-19 – 2017-08-12 · Disruptive Mood Dysregulation Disorder
What this study did
NCT02137616 · Central South University
2012-06 – 2014-12 · Psychotic Disorders
What this study did
NCT00956189 · National Taiwan University Hospital
2009-11 – 2012-10 · Metabolic Syndrome X
What this study did
NCT01562808 · Seoul National University Hospital
2009-01 – 2012-01 · Antipsychotics, Cognition, Brain Metabolism, Dopamine Receptor Occupancy
What this study did
NCT00947154 · Stanford University
2009-07 – 2010-07 · Trichotillomania
What this study did
NCT00468130 · University of Medicine and Dentistry of New Jersey
2006-05 – 2009-11 · Autism
What this study did
NCT00223418 · The University of Texas Health Science Center at San Antonio
2004-01 – 2007-06 · Schizophenia Disorder, Schizoaffective Disorder
What this study did
NCT00282139 · University of Florida
2004-01 – 2006-10 · Tourette's Syndrome
What this study did
Used as active comparator (34)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (9)
Major Depressive Disorder
NCT07153406 · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
2025-09-15 – 2029-01-15 · Depressive Disorder
What this study did
Schizophrenia
NCT06589817 · Chengdu Kanghong Pharmaceutical Group Co., Ltd.
2024-10 – 2026-12 · Acute Schizophrenia
What this study did
NCT06799559 · Qilu Pharmaceutical Co., Ltd.
2025-10-02 – 2026-12 · Schizophrenia
What this study did
NCT03198078 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2017-06-30 – 2023-04-03 · Schizophrenia
What this study did
NCT03874494 · Otsuka Beijing Research Institute
2019-11-27 – 2021-09-06 · Schizophrenia
What this study did
NCT01328093 · Denovo Biopharma LLC
2011-04 – 2012-10 · Schizophrenia
What this study did
NCT01009047 · Janssen Research & Development, LLC
2009-12 – 2012-06 · Schizophrenia
What this study did
NCT01104766 · Forest Laboratories
2010-04-23 – 2011-12-20 · Schizophrenia
What this study did
Phase 2/3 (1)
Schizophrenia
NCT01129674 · Denovo Biopharma LLC
2010-06 – 2012-10 · Schizophrenia
What this study did
Phase 2 (6)
Schizophrenia
NCT07703956 · Vigonvita Life Sciences
2026-07-31 – 2027-12-31 · Schizophrenia
What this study did
NCT07550387 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2024-05-23 – 2026-01-19 · SCHIZOPHRENIA 1 (Disorder)
What this study did
NCT01490086 · Reviva Pharmaceuticals
2011-12 – 2013-03 · Acute Schizophrenia, Schizoaffective Disorder
What this study did
NCT00845026 · Denovo Biopharma LLC
2009-03 – 2010-12 · Schizophrenia
What this study did
NCT00905307 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2009-07 – 2010-11 · Schizophrenia
What this study did
Phase 1 (4)
Schizophrenia
NCT05542264 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2022-11-15 – 2024-02-12 · Schizophrenia
What this study did
NCT05402111 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2022-06-13 – 2023-09-27 · Schizophrenia
What this study did
NCT01354353 · Denovo Biopharma LLC
2011-05 – 2012-03 · Schizophrenia
What this study did
Other / comorbidity
NCT05532254 · Future University in Egypt
2021-02-14 – 2021-03-11 · Healthy Subjects
What this study did
Phase 4 (11)
Major Depressive Disorder
NCT05554627 · VA Office of Research and Development
2023-10-27 – 2023-10-27 · Depressive Disorder, Major
What this study did
NCT00926835 · Ministry of Health & Welfare, Korea
2009-05 – 2015-07 · Major Depressive Disorder
What this study did
Schizophrenia
NCT06501339 · All India Institute of Medical Sciences, Bhubaneswar
2024-08-10 – 2026-03-31 · Clozapine Resistant Schizophrenia
What this study did
NCT04203056 · University of California, Los Angeles
2019-12-16 – 2022-10-01 · Schizophrenia, Schizoaffective Disorder, Depressive Type, Schizophreniform Disorder
What this study did
NCT01157351 · Janssen Scientific Affairs, LLC
2010-05 – 2013-12 · Schizophrenia
What this study did
NCT01193166 · Ortho-McNeil Janssen Scientific Affairs, LLC
2010-08 – 2012-09 · Schizophrenia
What this study did
NCT00330863 · Northwell Health
2006-05 – 2011-01 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00352339 · Inje University
2006-08 – 2010-12 · Schizophrenia
What this study did
NCT00299702 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2006-02 – 2009-01 · Schizophrenia, Psychotic Disorders
What this study did
Other / comorbidity
NCT05361993 · Children's Hospital of Fudan University
2024-06-01 – 2024-12-31 · Tic Disorders
What this study did
NCT00685334 · New York State Psychiatric Institute
2003-11 – 2006-09 · Eating Disorders
What this study did
Early phase / not applicable (3)
Schizophrenia
NCT02192723 · Beijing HuiLongGuan Hospital
2012-06 – 2014-06 · Schizophrenia
What this study did
Other / comorbidity
NCT06581302 · Shanghai Jiao Tong University School of Medicine
2024-09-01 – 2025-12-30 · Psychotic Disorders
What this study did
NCT02955654 · Shanghai Mental Health Center
2017-09-01 – 2018-12 · Obsessive-Compulsive Disorder
What this study did
Appears in other studies (17)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (5)
Bipolar Disorder
NCT01567527 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2012-08 – 2016-04 · Bipolar I Disorder
What this study did
Schizophrenia
NCT01129882 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2010-06-24 – 2018-12-06 · Schizophrenia
What this study did
NCT01683058 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2013-01 – 2014-02 · Schizophrenia
What this study did
NCT01663532 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2012-10 – 2013-09 · Schizophrenia
What this study did
Phase 2 (2)
Schizophrenia
NCT03557931 · Astellas Pharma Global Development, Inc.
2018-07-13 – 2019-10-21 · Schizophrenia
What this study did
NCT00509067 · Georgetown University
2007-11 – 2011-03 · Schizophrenia
What this study did
Phase 1 (3)
Schizophrenia
NCT03287505 · Otsuka Beijing Research Institute
2017-06-23 – 2019-11-08 · Schizophrenia
What this study did
NCT03285503 · Otsuka Beijing Research Institute
2018-08-17 – 2019-10-14 · Schizophrenia
What this study did
NCT01909466 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2013-07 – 2014-04 · Schizophrenia, Mental Disorder, Nervous System Diseases
What this study did
Phase 4 (5)
Bipolar Disorder
NCT07047651 · Dr. Stavroula Rakitzi
2025-06-04 – 2027-12-20 · Treatment Resistant Schizophrenia, Treatment Resistant Bipolar Disorder
What this study did
Schizophrenia
NCT03376763 · Korea Otsuka Pharmaceutical Co., Ltd.
2017-11-21 – 2021-11-19 · Schizophrenia, Antipsychotics, Long-Acting Injection, LAI, Aripiprazole
What this study did
NCT02237417 · University of Utah
2014-09-01 – 2020-07-30 · Schizophrenia
What this study did
NCT02360319 · Vanguard Research Group
2014-12-11 – 2019-03-31 · Schizophrenia
What this study did
NCT02040883 · Qingyun Yin
2014-02 – 2014-12 · Schizophrenia
What this study did
Early phase / not applicable (2)
Schizophrenia
NCT07547384 · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
2026-04-05 – 2027-11-05 · Schizophrenia
What this study did
NCT03019887 · Juntendo University
2011-04 – 2017-01 · Schizophrenia Relapse
What this study did

Competitive landscape

5 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Bipolar Disorder: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Aripiprazole (Abilify): this drugApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptornot yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify Maintena)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D2/D3 and serotonin 5-HT1A receptor, Dopamine D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
AsenapineApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Cariprazine (Vraylar)ApprovedSmall moleculeDopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote ER)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote)ApprovedSmall moleculeGABAergic neurotransmissionPartial signalFeatured results are non-efficacy only in this race
Iloperidone (Fanapt)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
LamotrigineApprovedSmall moleculeVoltage-gated sodium channelnot yet gradedNo reviewed efficacy summary in this indication
Milsaperidone (VHX-896)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signalNo reviewed efficacy summary in this indication
Olanzapine (Zyprexa)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Olanzapine / Samidorphan (Lybalvi)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist); mu-opioid receptor (antagonist)Reliable signalNo reviewed efficacy summary in this indication
Quetiapine (Seroquel XR)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Quetiapine (Seroquel)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Risperdal Consta)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Risperdal)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Rykindo)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Uzedy)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
ZiprasidoneApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Dexmedetomidine (Igalmi)Phase 3Small moleculeAlpha-2 adrenergic receptor (agonist)Reliable signalNo reviewed efficacy summary in this indication
Loxapine (Adasuve)Phase 3Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signalNo reviewed efficacy summary in this indication
Xanomeline / Trospium Chloride (Cobenfy)Phase 3Small moleculeMuscarinic M1/M4 receptor (agonist/antagonist combination)not yet gradedNo reviewed efficacy summary in this indication
ALTO-100Phase 2Small moleculeFirst-in-class oral small molecule neural plasticity enhancernot yet gradedNo reviewed efficacy summary in this indication
BrenipatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
ElunetiromPhase 2Small moleculeThyroid hormone receptor-betanot yet gradedNo reviewed efficacy summary in this indication
IcalcaprantPhase 2Small moleculeKappa-opioid receptor (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
Lithium Salicylate / L-Proline (AL001)Phase 1/2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
ABBV-1042
Phase 1(overall)
Small moleculeMuscarinic M4 receptornot yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify MyCite)DiscontinuedCombinationDopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(10 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Aripiprazole (Abilify) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 1/2Depression, SequestraRecruiting
Est. primary completion 2026-12-31 · NCT05814640 · CT.gov ↗
What to watch
2027 (4)
June 2027 (3)
Phase 4Major Depressive DisorderNot yet recruiting
Est. primary completion 2027-06 · NCT07011693 · CT.gov ↗
What to watch
Phase 1Stuttering, AdultRecruiting
Est. primary completion 2027-06-30 · NCT07215884 · CT.gov ↗
What to watch
Phase 2Obsessive-Compulsive DisorderRecruiting
Est. primary completion 2027-06-30 · NCT04539951 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Trichotillomania (Hair-Pulling Disorder), DermatillomaniaNot yet recruiting
Est. primary completion 2027-12 · NCT05545891 · CT.gov ↗
What to watch
2028 (1)
May 2028 (1)
Phase 2Post-acute Infectious Syndrome (PAIS), Post-COVID-19 Condition (PCC or Long COVID)Not yet recruiting
Est. primary completion 2028-05-15 · NCT07714213 · CT.gov ↗
What to watch
2029 (2)
March 2029 (1)
Phase 2Major Depressive DisorderNot yet recruiting
Est. primary completion 2029-03-15 · NCT07810738 · CT.gov ↗
What to watch
December 2029 (1)
Phase 4Psychosis; AcuteRecruiting
Est. primary completion 2029-12-01 · NCT07483294 · CT.gov ↗
What to watch
2030 (2)
February 2030 (1)
Phase 4Bipolar DisorderActive not recruiting
Est. primary completion 2030-02-28 · NCT06433635 · CT.gov ↗
What to watch
July 2030 (1)
Phase 4SchizophreniaRecruiting
Est. primary completion 2030-07-30 · NCT06969755 · CT.gov ↗
What to watch

See the full readout calendar ↗